Cogent BiosciencesCOGT +0.26%25 PB Ratio is 11.97 as of Jun. 29, 2026, which is 345% above its 10-year median of 2.69. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,232 Biotechnology companies, Cogent Biosciences ranks worse than 88.39% on this metric.
Cogent Biosciences Inc stock PB Ratio (=11.97) is close to 10-year high of 13.16.
The historical rank and industry rank for Cogent Biosciences's PB Ratio or its related term are showing as below:
COGT'
s PB Ratio Range Over the Past 10 Years
Min: 0.31 Med: 2.69 Max: 13.16
Current: 11.97
During the past 11 years, Cogent Biosciences's highest PB Ratio was 13.16. The lowest was 0.31. And the median was 2.69.
COGT's PB Ratio is ranked worse than 88.39% of 1232
companies
in the Biotechnology industry
Industry Median: 2.835
vs COGT: 11.97
During the past 12 months, Cogent Biosciences's average Book Value Per Share Growth Rate was 226.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.70% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Cogent Biosciences was 7.70% per year. The lowest was -28.40% per year. And the median was -15.70% per year.
Back to Basics: PB Ratio
Cogent Biosciences (NAS:COGT) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cogent Biosciences PB Ratio Related Terms
Cogent Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Cogent Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cogent Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cogent Biosciences (COGT) has a PB Ratio of 11.97 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cogent Biosciences and its competitors. This is 345% above median its historical median of 2.69. Over the past decade, Cogent Biosciences' PB Ratio has ranged from 0.31 to 13.16. According to the industry distribution chart, Cogent Biosciences ranks #1089 out of 1232 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Cogent Biosciences' PB Ratio too high?
Cogent Biosciences' current PB Ratio of 11.97 is 345% above median its 10-year median of 2.69. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 13.16. The Biotechnology industry median PB Ratio is 2.84. Cogent Biosciences' value of 11.97 is 322.2% above this industry median. Based on the distribution chart, Cogent Biosciences ranks #1089 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' PB Ratio compare to SRRK and CGON?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #1089 out of 1232 companies for PB Ratio. This places Cogent Biosciences in the lower half of its industry. The industry median PB Ratio is 2.84. Cogent Biosciences' value of 11.97 is 322.2% above this benchmark. Historically, Cogent Biosciences' own PB Ratio has ranged from 0.31 to 13.16 over the past decade. While the company's 10-year median is 2.69 vs. the industry median of 2.84, Cogent Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.84, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogent Biosciences's current PB Ratio of 11.97 is 322.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cogent Biosciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogent Biosciences's current PB Ratio is 11.97, which is 345% above median its own 10-year median of 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current PB Ratio of 11.97. The current PB Ratio is 11.97, which is 345% above median its 10-year median of 2.69 and 322.2% above the Biotechnology industry median of 2.84. Cogent Biosciences' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current PB Ratio is 11.97 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
25GF Score
Get the complete analysis for COGT
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
